Evidence map›Paper›PMID 38543026›Full record

ArticleMolecules (Basel, Switzerland)2024

Neurotensin (8-13) and Neuromedin N Neuropeptides Radiolabelling with Copper-64 Produced on Solid or Liquid Targets.

Diana Cocioabă, Alexandra I Fonseca, Radu Leonte, Ivanna Hrynchak, Roxana Tudoroiu-Cornoiu, Sergio J C do Carmo, Bogdan Burghelea, Simona Băruță, Ana Rita Almeida, Radu Șerban and 3 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Diana CocioabăRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.ORCID 0000-0002-0445-0581
Alexandra I FonsecaICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-1924-178X
Radu LeonteRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.ORCID 0000-0002-2929-8280
Ivanna HrynchakICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-1671-7861
Roxana Tudoroiu-CornoiuRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.ORCID 0000-0001-7886-9900
Sergio J C do CarmoICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-4631-7268
Bogdan BurgheleaRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.
Simona BăruțăRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.
Ana Rita AlmeidaICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.
Radu ȘerbanRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.
Anca DinischiotuFaculty of Biology, Doctoral School of Biology, University of Bucharest, 050095 Bucharest, Romania.
Antero J AbrunhosaICNAS Pharma, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-4145-854X
Dana NiculaeRadiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), 077125 Măgurele, Romania.ORCID 0000-0002-4769-843X

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii ERANET 281/2022
6 · The paper itself

Abstract

On the verge of a theranostic approach to personalised medicine, copper-64 is one of the emerging radioisotopes in nuclear medicine due to its exploitable nuclear and biochemical characteristics. The increased demand for copper-64 for preclinical and clinical studies has prompted the development of production routes. This research aims to compare the (p,n) reaction on nickel-64 solid versus liquid targets and evaluate the effectiveness of [

Indexed as

Copper RadioisotopesPeptide FragmentsProtonsCopperNeurotensinRadioisotopesRadiopharmaceuticalsCopperCopper-64Copper Radioisotopesneuromedin NNeurotensinneurotensin (8-13)Peptide FragmentsProtonsRadioisotopesRadiopharmaceuticalscopper-64liquid targetneuropeptidessolid targettheranostic

Identifiers

PMID38543026
PMCPMC10974674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.